trazodone has been researched along with Degenerative Diseases, Central Nervous System in 3 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trazodone is a widely used antidepressant that is also useful in the control of agitation and insomnia in Alzheimer's disease." | 2.72 | The effects of trazodone on human cognition: a systematic review. ( Gonçalo, AMG; Vieira-Coelho, MA, 2021) |
| "Trazodone is a drug that was introduced in the clinic almost 40 years ago." | 1.48 | Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. ( Settimo, L; Taylor, D, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, C | 1 |
| Dakin, RS | 1 |
| Williamson, J | 1 |
| Newton, J | 1 |
| Steven, M | 1 |
| Colville, S | 1 |
| Stavrou, M | 1 |
| Gregory, JM | 1 |
| Elliott, E | 1 |
| Mehta, AR | 1 |
| Chataway, J | 1 |
| Swingler, RJ | 1 |
| Parker, RA | 1 |
| Weir, CJ | 1 |
| Stallard, N | 1 |
| Parmar, MKB | 1 |
| Macleod, MR | 1 |
| Pal, S | 1 |
| Chandran, S | 1 |
| Gonçalo, AMG | 1 |
| Vieira-Coelho, MA | 1 |
| Settimo, L | 1 |
| Taylor, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial[NCT04302870] | Phase 2/Phase 3 | 800 participants (Anticipated) | Interventional | 2020-02-27 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for trazodone and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
The effects of trazodone on human cognition: a systematic review.
Topics: Antidepressive Agents, Second-Generation; Cognition; Cognitive Dysfunction; Cross-Over Studies; Dose | 2021 |
1 trial available for trazodone and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Memantine; Motor Neuron Disease; Neurode | 2022 |
1 other study available for trazodone and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets.
Topics: Animals; Antidepressive Agents; Brain; Dementia; Depression; Depressive Disorder; Humans; Hypnotics | 2018 |